BamSEC and AlphaSense Join Forces
Learn More

Actuate Therapeutics, Inc. – Material Contracts

NASDAQ: ACTU    
Share price (11/6/26): $0.33    
Market cap (11/6/26): $18.1 million

Material Contracts Filter

EX-10.21
from S-1 6 pages [Continued on Next Page] 1
12/34/56
EX-10.20
from S-1 6 pages [Continued on Next Page] 1
12/34/56
EX-10.2
from 8-K 8 pages Form of Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 27 pages Form of Securities Purchase Agreement
12/34/56
EX-10.5
from 10-Q 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.4
from 10-Q 2 pages First Amendment to Employment Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Tenth Amendment to Employment Agreement
12/34/56
EX-10.2
from 8-K 25 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 85 pages Common Stock Purchase Agreement Dated as of March 27, 2025 by and Between Actuate Therapeutics, Inc. and B. Riley Principal Capital II, LLC
12/34/56
EX-10.1
from 10-Q 2 pages Actuate Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.4
from S-1/A 30 pages Exclusive License Agreement With Equity
12/34/56
EX-10.3
from S-1/A 3 pages Actuate Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.14
from S-1/A 6 pages Actuate Therapeutics, Inc. 2024 Stock Incentive Plan Restricted Stock Unit Grant Notice
12/34/56
EX-10.13
from S-1/A 7 pages Actuate Therapeutics, Inc. 2024 Stock Incentive Plan Stock Option Grant Notice
12/34/56
EX-10.6
from S-1/A 57 pages Employment Agreement
12/34/56
EX-10.3
from S-1/A 3 pages Actuate Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.12
from S-1 18 pages Actuate Therapeutics, Inc. Indemnification Agreement
12/34/56
EX-10.11
from S-1 16 pages Actuate Therapeutics, Inc. Indemnification Agreement
12/34/56
EX-10.10
from S-1 7 pages Form of Indemnification Agreement
12/34/56
EX-10.9
from S-1 24 pages This Employment Agreement (This “Agreement”), Is Entered Into to Be Effective as of June 1, 2024 (The “Effective Date”), by and Between Actuate Therapeutics, Inc., a Delaware Corporation (The “Company”), and Paul Lytle, an Individual Currently Residing at [●] (The “Employee”). Whereas, Company Desires to Employ the Employee on the Terms, Conditions and for the Consideration Hereinafter Set Forth, and the Employee Is Willing to Serve as an Employee of the Company on Such Terms and Conditions and for Such Consideration. Now Therefore, for and in Consideration of the Mutual Promises, Covenants and Obligations Contained Herein, the Company and the Employee Hereby Agree as Follows
12/34/56